|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS10223|
The global pre-clinical imaging (in-vivo) market is growing significantly due to development of high resolution and sensitive imaging devices with various applications in the industry. Massive unexplored market in pre-clinical imaging (in-vivo) industry of developing economies are creating ample opportunities for the pre-clinical imaging (in-vivo) market to grow at a considerable rate in the coming years. Further, technological advancement in pre-clinical imaging will support the growth of the global pre-clinical imaging (in-vivo) market in the coming years.
Pre-clinical (in-vivo) imaging is bridging a gap between the vivo clinical research and vitro exploratory. It is increasingly being deployed across the drug development process, specifically in oncology therapeutic area. The advanced research and development facilities and new product developments of the companies are supporting the growth of pre-clinical imaging (in-vivo) industry. Moreover, integration of pre-clinical MRI systems with other imaging modalities is also expected to propel the growth of the global pre-clinical imaging market in coming years.
On the basis of type of modalities of pre-clinical imaging (in-vivo), the market can be categorized as optical imaging systems, pre-clinical nuclear imaging systems, micro-magnetic resonance imaging (MRI), micro-ultrasound, micro-CT, pre-clinical photoacoustic imaging system, pre-clinical magnetic particle imaging system and others. The optical imaging system lead the pre-clinical imaging (in-vivo) market, by type of modalities category; whereas, the pre-clinical nuclear imaging system segment is expected to grow with the fastest rate in the coming years due to rising adoption of pre-clinical imaging and development of technologically hybrid nuclear imaging systems.
The pre-clinical imaging (in-vivo) market can be categorized on the basis of reagents as pre-clinical optical imaging reagents, pre-clinical nuclear imaging reagents, pre-clinical MRI contrast agents, pre-clinical ultrasound contrast agents, and pre-clinical CT contrast agents.
Some of the factors driving the growth of the global pre-clinical imaging (in-vivo) market are increasing usage of pre-clinical imaging as a drug discovery and development tool, increasing number of pre-clinical research activities, technological development in molecular imaging and rising demand of multi-modality imaging technology in pre-clinical research. And the factors restraining the growth of the pre-clinical imaging (in-vivo) market are high execution cost of pre-clinical imaging system, technology inadequacy for standalone pre-clinical imaging modalities, and limited funding for lifescience research. In addition, high cost and short half-life of PET radioisotopes also inhibits the growth of micro-PET systems in developing regions.
Geographically, North America will be leading the global pre-clinical imaging (in-vivo) market in the coming years due to high volume pre-clinical research, entrenched infrastructure to conduct pre-clinical research, rising government funding, and easy availability and accessibility of resources. Asia-Pacific is the fastest growing region in the global pre-clinical imaging (in-vivo) market; attributing to the growth are factors such as increasing government funding for development of pharmaceutical companies, and rising research and development activities by pharmaceutical and biotechnology companies in the region. Moreover, the pre-clinical imaging (in-vivo) market is growing due to increasing number of contract research organizations in the emerging countries, such as India and China, of Asia-Pacific region.
Some of the companies operating in the pre-clinical imaging (in-vivo) market are Perkinelmer Inc., Mr Solutions Ltd., Mediso Ltd., Bruker Corporation, Trifoil Imaging, Fujifilm Visualsonics Inc., Biospace Lab S.A., Milabs B.V., Li-Cor Biosciences, Thermo Fisher Scientific, Agilent Technologies and Aspect Imaging.